Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy

Testicular Neoplasms

Neurotoxicity
Medications of interest
General health
Family history

Questionnaire

Indiana University Melvin and Bren Simon Cancer Center

The Platinum Study Comparison Group

Sequelae of Treatment in Survivors of Testicular Cancer Creation of a Non-exposed Comparison Group for the Platinum Study

The proportion of patients from this study will be compared to the proportion of patients with The Platinum Study.

Lawrence Einhorn

Distinguished Professor of Medicine

Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.

Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.

Testicular Cancer

Androgel (Testosterone gel)

Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.

Placebo gel

University Medical Center Groningen

Short-term Testosterone Replacement in Testicular Cancer Survivors

Short-term Testosterone Replacement in Testicular Cancer Survivors to Treat Overweight and Improve Cardiometabolic Risk: A Pilot Study

To assess the effects of 20 weeks of treatment with testosterone gel on fat mass as measured using full body dual X-ray absorptiometry (DEXA scan).

To assess the effects of 20 and 40 weeks of treatment with testosterone gel on obesity

To assess the effects of 20 and 40 weeks of treatment with testosterone gel on signs and symptoms of hypogonadism

J. Nuver

Principal Investigator

Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis (NKI-AVL)

University Medical Center Groningen (UMCG)

Maastricht University Medical Center (MUMC)

Instituto Portuges de Oncologia Francisco Gentil (IPOLFG)

UniversitatsSpital Zurich

Vascular Fingerprint Validation Study

Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study

Primary outcome is development of arterial cardiovascular events within the first year after start of chemotherapy. Events taken into account are: myocardial infarction (WHO ICD-10 I20-I25), ischemic cerebrovascular accidents (WHO ICD-10 I63-I66 and G45) or infarction in other specific organ systems (WHO ICD-10 K76.3, K55, D73.5, M62.2, N28.0)

J.A. Gietema

Principal investigator

Patients with disseminated testicular cancer

the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.

Dexa scan

the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.

audiogram

the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year.

measurement of heart rate variability and baroreflex sensitivity

Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year.

Glucose tolerance assessment

a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).

oral nutrition supplements

Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.

Two day food records

A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).

Food Frequency Questionnaire

Taste, Smell and Chemotherapy (TASTY)

Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy

To investigate the nature, prevalence, and duration of taste and smell changes in patients with disseminated testicular cancer treated with cisplatin based chemotherapy (BEP (Bleomycin, Etoposide, cisPlatin) or EP (Etoposide, cisPlatin)).
Tests used are: Gustatory function will be tested using filter-paper taste strips to measure recognition thresholds for sweet, salty, sour and bitter taste. Olfactory function will be tested using Sniffin' Sticks to measure odor threshold, discrimination and recognition.

To explore the short- and long-term consequences of taste and smell changes in relation to food preference, dietary intake, and quality of life. Tests used: QoL questionnaires (EORTC QLQ-C30). Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy. A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake.

To investigate the appreciation of medical food products in patients with disseminated testicular cancer treated with cisplatin based chemotherapy.
A set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products.
Food preference will be investigated by showing standardized photographs of sweet and savory food products, varying in fat and protein content.

To assess whether changes in taste and smell are related to the metabolic syndrome.
Tests used: glucose tolerance test and DEXA scan.

To assess whether chemotherapy induced neurotoxicity is related to changes in taste and smell.
TEsts used: audiogram, assessment of heart rate variability and baroreflex sensitivity.

testicular neoplasms/lihavuus

The Platinum Study Comparison Group

Short-term Testosterone Replacement in Testicular Cancer Survivors

Vascular Fingerprint Validation Study

Taste, Smell and Chemotherapy (TASTY)

Täydellisin lääketieteellinen tietokanta tieteen tukemana